2016 February 10

Article Blood: What is going on between defibrotide and endothelialcells? Snapshots reveal the hot spots of their romance

The Barcelona Endothelium Team (BET), at the IJC has recently published a paper in Blood

Defibrotide (DF) has been given the go ahead by theEuropean Medicines Agency (EMA)to treat Sinusoidal Obstruction Syndrome, a frequent complication after the transplant of hematopoietic cells. The role of DF as an endothelial protector has been recognized for some time, although the precise mechanism is not fully known. The aim of the present study is to investigate the interaction of DF with endothelialcells. The results in the paper contribute to a better understanding of the precise mechanisms by which DF acts as a therapeutic and potentially preventive agent on the endothelial damage that underlies differentdiseases.
+ info: Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/26755708
Journal Blood: http://www.bloodjournal.org/content/early/2016/01/11/blood-2015-10-676114.long?sso-checked=true